Signaturefd LLC Acquires 653 Shares of Smith & Nephew plc (NYSE:SNN)

Signaturefd LLC increased its holdings in Smith & Nephew plc (NYSE:SNN) by 4.3% during the 4th quarter, Holdings Channel reports. The firm owned 15,772 shares of the medical equipment provider’s stock after buying an additional 653 shares during the period. Signaturefd LLC’s holdings in Smith & Nephew were worth $388,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. PNC Financial Services Group Inc. grew its stake in shares of Smith & Nephew by 4.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider’s stock worth $224,000 after purchasing an additional 399 shares during the last quarter. Bleakley Financial Group LLC grew its stake in shares of Smith & Nephew by 3.5% in the fourth quarter. Bleakley Financial Group LLC now owns 17,704 shares of the medical equipment provider’s stock worth $435,000 after purchasing an additional 596 shares during the last quarter. Principal Securities Inc. grew its stake in shares of Smith & Nephew by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 691 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Smith & Nephew by 31.8% in the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider’s stock worth $73,000 after purchasing an additional 718 shares during the last quarter. Finally, Townsquare Capital LLC grew its stake in shares of Smith & Nephew by 5.4% in the third quarter. Townsquare Capital LLC now owns 14,759 shares of the medical equipment provider’s stock worth $460,000 after purchasing an additional 761 shares during the last quarter. 25.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have commented on SNN. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 26th. Canaccord Genuity Group restated a “hold” rating and issued a $27.00 price objective on shares of Smith & Nephew in a report on Monday. Finally, UBS Group lowered shares of Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $27.00.

Smith & Nephew Price Performance

SNN stock opened at $28.47 on Friday. The firm has a 50 day moving average price of $26.68 and a 200-day moving average price of $27.11. Smith & Nephew plc has a 52-week low of $23.65 and a 52-week high of $31.72. The firm has a market capitalization of $12.45 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 1.26 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

Smith & Nephew Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.447 per share. This represents a dividend yield of 2.5%. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. The ex-dividend date of this dividend is Friday, March 28th. Smith & Nephew’s dividend payout ratio (DPR) is presently 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.